MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaomeng, Wojtkowiak, Jonathan W., Martinez, Gary V., Cornnell, Heather H., Hart, Charles P., Baker, Amanda F., Gillies, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://www.ncbi.nlm.nih.gov/pubmed/27227903
http://dx.doi.org/10.1371/journal.pone.0155289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://www.ncbi.nlm.nih.gov/pubmed/27227903
http://dx.doi.org/10.1371/journal.pone.0155289

Ejemplares similares